Pharma and BioTech Daily

Jaksot

• 
  Ultragenyx’s $4M Fayuvi FDA Approval Breakthrough | Pharma and Biotech Daily 21.09.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements and strategic shifts shaping the future of this dynamic industry. The FDA has recently approved Ultragenyx's gene therapy, Fayuvi, for a rare neurodegenerative disorder, marking a significant milestone in the realm of precision medicine. Gene therapies like Fayuvi offer a beacon of hope for conditions...
• 
  Bayer's Kerendia Secures 3rd FDA Approval | Pharma and Biotech Daily 18.09.2026 4min

  Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care. Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist pla...
• 
  Novartis Acquires Sironax Platform for $125M | Pharma and Biotech Daily 17.09.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of dynamic and significant advancements across the industry, from strategic acquisitions to regulatory shifts and scientific innovations. In a bold move, Novartis has acquired Sironax's blood-brain barrier delivery platform for $125 million. This acquisition marks a strategic enhancement in Novartis's ability to deliver therapi...
• 
  GSK Acquires Chimagen's Tech for $750M | Pharma and Biotech Daily 16.09.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant strides and strategic maneuvers reshaping the landscape of healthcare and drug development. Kicking things off, GlaxoSmithKline (GSK) has made headlines with its acquisition of Chimagen Biosciences' trispecific T cell engager technology, targeting multiple myeloma. This move, valued at up to $750 million, highlights ...
• 
  Scholar Rock's $20B Pharma Shakeup & More | Pharma and Biotech Daily 15.09.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today’s episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care. Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal m...
• 
  Moderna's $1B mRNA Cancer Vaccine Boosts Personalized Meds | Pharma and Biotech Daily 14.09.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. First, let's delve into the innovative work being done by Grove Biopharma. Founded in 2020 in Chicago, this company is at the forefront of developing polymer-peptide hybrids to target intracellular protein-protein interactions, areas traditionally deemed undruggable. These interactions are crucial regulatory components in numerous cellular processes and are imp...
• 
  FDA Expands Bayer's Hyrnuo Approval | Pharma and Biotech Daily 11.09.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant advancements and challenges that are shaping the future of drug development, regulatory landscapes, and industry innovations. Starting with a major milestone in personalized cancer therapy, the FDA has expanded Bayer's approval for Hyrnuo (zipalertinib) to include its use as a first-line treatment for HER2-mutant non-small c...
• 
  Sandoz Invests $2.5B in Biosimilars Network | Pharma and Biotech Daily 10.09.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself ...
• 
  AstraZeneca's $116M FDA Win: New Breast Cancer Drug | Pharma and Biotech Daily 09.09.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care. AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to t...
• 
  FDA Approves Alzheimer's Drug: Major $ Breakthrough | Pharma and Biotech Daily 08.09.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's episode, we're diving into a series of breakthroughs and significant updates that are shaping the landscape of medicine and treatment. Let's start with a remarkable development in the realm of personalized medicine. Researchers have announced a breakthrough in gene-editing technology that holds promise for treating a range of genetic disorders. This ...
• 
  Ionis' Zanvastro FDA Approved: $771M Partnership Impact | Pharma and Biotech Daily 07.09.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of pivotal advances and industry dynamics that are shaping the future of healthcare. The U.S. Food and Drug Administration has recently granted approval to Ionis Pharmaceuticals' Zanvastro, a breakthrough in treating Alexander disease. This condition, a rare neurodegenerative disorder caused by mutations in the glial fibrillary aci...
• 
  Summit & Akeso's Ivonescimab Beats Keytruda in NSCLC Phase 3 | Pharma and Biotech Daily 04.09.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating updates that are shaping the future of medicine and patient care. First on our agenda is uniQure's ambitious step toward accelerated U.S. marketing approval for AMT-130, a gene therapy targeting Huntington's disease. This move signifies a potential breakthrough in treating rare neurological disorders with genetic...
• 
  AstraZeneca & Roche Secure EU Breast Cancer Approval | Pharma and Biotech Daily 03.09.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into groundbreaking scientific advancements, crucial regulatory updates, and strategic industry movements that are shaping the future of patient care and drug development. AstraZeneca, in collaboration with Daiichi Sankyo, has achieved a significant milestone with their antibody-drug conjugate, Enhertu, combined with Roche's Perjeta. This combin...
• 
  Novartis' Rhapsido Hits Phase 3 Goals for MS | Pharma and Biotech Daily 02.09.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the dynamic landscape of the industry, highlighting significant scientific breakthroughs, strategic partnerships, and regulatory updates that are reshaping healthcare as we know it. Novartis recently announced a major milestone with its BTK inhibitor, Rhapsido, which met its Phase 3 clinical trial goals for treating relapsing multiple sclero...
• 
  Eli Lilly Acquires Merida for $2.9B | Pharma and Biotech Daily 01.09.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The current landscape in the pharmaceutical and biotech industries is a tapestry of dynamic mergers, clinical trial advancements, regulatory approvals, and strategic partnerships. A major highlight is Eli Lilly's acquisition of Merida Biosciences for up to $2.9 billion. This move exemplifies the industry's strategic focus on expanding portfolios specifically in...
• 
  Eli Lilly's $173M FDA Win: Mounjaro Approved! | Pharma and Biotech Daily 31.08.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory milestones that underscore the industry's commitment to addressing complex health challenges with innovative therapeutics and strategic investments. Eli Lilly has achieved a major breakthrough with the FDA approval of Mounjaro (tirzepatide), a dual GLP-1/GIP agonist designed to reduce card...
• 
  Revolution Medicines' $2.25B FDA Approval Milestone | Pharma and Biotech Daily 28.08.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore groundbreaking advancements, regulatory updates, and strategic partnerships shaping the future of patient care and drug development. Revolution Medicines has achieved a significant milestone with the FDA approval of its RAS inhibitor, daraxonrasib, for metastatic pancreatic cancer treatment. This approval follows an impressive presentation at ...
• 
  Revolution Medicines FDA Win: RAS Inhibitor Approved | Pharma and Biotech Daily 27.08.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive right into today's top stories, where pioneering advancements and strategic shifts are reshaping how we understand and treat complex diseases. In recent developments, Akeso's PD-1xVEGF bispecific antibody ivonescimab is making waves beyond its initial use in non-small cell lung cancer. The successful completion of a Phase 3 trial for biliary tract ca...
• 
  FDA Extends Capricor Review: $2.25B McKesson Deal | Pharma and Biotech Daily 26.08.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest happenings in these dynamic sectors, where scientific advancements, regulatory decisions, and strategic business initiatives are continuously reshaping the landscape of healthcare. Starting with a significant regulatory update, the FDA has granted Capricor Therapeutics a three-month extension to review Phase 3 data for Deramiocel...
• 
  Roche & Hanmi's $2.5B Obesity Drug Deal | Pharma and Biotech Daily 25.08.2026 8min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the rapidly evolving landscape of pharmaceutical and biotechnology sectors, several significant developments have marked recent progress in drug development, clinical trials, regulatory approvals, and industry partnerships. A landmark partnership between Roche and Hanmi Pharm has been established to develop HM17321, a promising weight loss drug. This collabo...